European Spec Pharma Testing New Niches: Emerging Markets, Novel Products
Many struggling European specialty pharma companies are grappling with whether to move outside the traditional business mold by venturing beyond Europe, including into emerging markets, and how to develop differentiated products with potential for transformative growth.
You may also be interested in...
Sinclair Pharma's merger with IS Pharma aims to create a more attractive European licensee; also to aid expansion into emerging markets.
As more companies of all sizes embrace rare diseases – lured in part by supposed lower regulatory and reimbursement hurdles – some niche markets are beginning to look rather busy.
Pricing pressure in Europe is hardly new, but it became a much bigger concern in 2010. The last 18 months have seen some of the most severe and certainly the most numerous, price cuts across the region. Although individual European countries represent only a small share of Big Pharma revenues, the EU as a whole is the world's second-largest market in sales terms, only slightly smaller than the U.S.